Absence of Novel CYP4F2 and VKORC1 Coding Region DNA Variants in Patients Requiring High Warfarin Doses

OBJECTIVE: Warfarin is an FDA-approved oral anticoagulant for long-term prevention of thromboembolism. Substantial inter-individual variation in dosing requirements and the narrow therapeutic index of this widely-prescribed drug make safe initiation and dose stabilization challenging. Single nucleot...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Burmester, James K., Berg, Richard L., Glurich, Ingrid, Yale, Steven H., Schmelzer, John R., Caldwell, Michael D.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Marshfield Clinic 2011
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3251364/
https://ncbi.nlm.nih.gov/pubmed/21562135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3121/cmr.2011.951
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg